Skip to Content

IQVIA Holdings Inc IQV

Morningstar Rating
$251.56 −0.89 (0.35%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

IQVIA Earnings: Robust Demand for Outsourced Clinical Trials Drives Growth; Shares Fairly Valued

IQVIA reported strong year-end results highlighted by revenue of $14.9 billion, representing 4% growth versus the prior year. Despite a challenging macroeconomic environment, demand for IQVIA’s clinical research services remains resilient. Investors reacted favorably, sending the stock up 12% based on the quarter’s solid results, healthy backlog, net new business, and positive outlook for 2024. We maintain our fair value estimate of $250 per share, and we now view shares as fairly valued as they have moved into 3-star territory.

Price vs Fair Value

IQV is trading at a 1% premium.
Price
$251.56
Fair Value
$661.00
Uncertainty
Medium
1-Star Price
$522.40
5-Star Price
$846.00
Economic Moat
Dblczyh
Capital Allocation
Fpkspxc

Bulls Say, Bears Say

Bulls

IQVIA’s leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.

Bears

The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IQV is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$252.45
Day Range
$250.01253.33
52-Week Range
$167.42253.33
Bid/Ask
$210.89 / $251.56
Market Cap
$45.79 Bil
Volume/Avg
642,060 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
24.64
Price/Sales
3.13
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
2.17%

Company Profile

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
87,000

Competitors

Valuation

Metric
IQV
ICLR
MEDP
Price/Earnings (Normalized)
24.6424.0945.28
Price/Book Value
7.472.9622.12
Price/Sales
3.133.386.79
Price/Cash Flow
19.2921.4839.17
Price/Earnings
IQV
ICLR
MEDP

Financial Strength

Metric
IQV
ICLR
MEDP
Quick Ratio
0.761.160.59
Current Ratio
0.861.210.64
Interest Coverage
3.122.99688.87
Quick Ratio
IQV
ICLR
MEDP

Profitability

Metric
IQV
ICLR
MEDP
Return on Assets (Normalized)
7.32%6.18%20.56%
Return on Equity (Normalized)
32.37%11.98%69.64%
Return on Invested Capital (Normalized)
12.78%10.27%48.77%
Return on Assets
IQV
ICLR
MEDP
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncClzg$221.8 Bil
DHR
Danaher CorpKthwrq$189.5 Bil
IDXX
IDEXX Laboratories IncPbytkbr$47.4 Bil
A
Agilent Technologies IncLxslm$41.9 Bil
MTD
Mettler-Toledo International IncPjhwr$27.6 Bil
ICLR
Icon PLCJblym$27.3 Bil
ILMN
Illumina IncShpjttr$21.9 Bil
WAT
Waters CorpQbhf$20.5 Bil
LH
Laboratory Corp of America HoldingsGmzsyqf$18.4 Bil

Sponsor Center